JP2014523252A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014523252A5 JP2014523252A5 JP2014520633A JP2014520633A JP2014523252A5 JP 2014523252 A5 JP2014523252 A5 JP 2014523252A5 JP 2014520633 A JP2014520633 A JP 2014520633A JP 2014520633 A JP2014520633 A JP 2014520633A JP 2014523252 A5 JP2014523252 A5 JP 2014523252A5
- Authority
- JP
- Japan
- Prior art keywords
- dendritic cell
- functionally equivalent
- tolerogenic dendritic
- equivalent variant
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004443 dendritic cell Anatomy 0.000 claims 20
- 230000003614 tolerogenic effect Effects 0.000 claims 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims 14
- 239000002157 polynucleotide Substances 0.000 claims 13
- 102000040430 polynucleotide Human genes 0.000 claims 13
- 108091033319 polynucleotide Proteins 0.000 claims 13
- 102000016550 Complement Factor H Human genes 0.000 claims 9
- 108010053085 Complement Factor H Proteins 0.000 claims 9
- 102100037080 C4b-binding protein beta chain Human genes 0.000 claims 8
- 101000740689 Homo sapiens C4b-binding protein beta chain Proteins 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 8
- 208000026278 immune system disease Diseases 0.000 claims 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 229920001184 polypeptide Polymers 0.000 claims 7
- 102000001708 Protein Isoforms Human genes 0.000 claims 6
- 108010029485 Protein Isoforms Proteins 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 4
- 206010020751 Hypersensitivity Diseases 0.000 claims 4
- 206010040047 Sepsis Diseases 0.000 claims 4
- 206010052779 Transplant rejections Diseases 0.000 claims 4
- 208000026935 allergic disease Diseases 0.000 claims 4
- 208000024908 graft versus host disease Diseases 0.000 claims 4
- 230000009610 hypersensitivity Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 210000003289 regulatory T cell Anatomy 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 230000000495 immunoinflammatory effect Effects 0.000 claims 3
- 239000000463 material Substances 0.000 claims 3
- IGZDHJLGVYRKAC-UHFFFAOYSA-N 1-methyl-3-[2-(1-methylbenzimidazol-2-yl)sulfanylethyl]benzimidazole-2-thione Chemical compound C1=CC=C2N(C)C(SCCN3C(N(C)C4=CC=CC=C43)=S)=NC2=C1 IGZDHJLGVYRKAC-UHFFFAOYSA-N 0.000 claims 2
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 claims 2
- 102100035793 CD83 antigen Human genes 0.000 claims 2
- 102100032406 Cytosolic carboxypeptidase 6 Human genes 0.000 claims 2
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 2
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 2
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 claims 2
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims 2
- 101000868785 Homo sapiens Cytosolic carboxypeptidase 6 Proteins 0.000 claims 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims 1
- 102100032891 Superoxide dismutase [Mn], mitochondrial Human genes 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 108010045815 superoxide dismutase 2 Proteins 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11382240A EP2557089A2 (en) | 2011-07-15 | 2011-07-15 | Compositions and methods for immunomodulation |
| EP11382240.7 | 2011-07-15 | ||
| PCT/EP2012/063932 WO2013010998A2 (en) | 2011-07-15 | 2012-07-16 | Compositions and methods for immunomodulation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017130703A Division JP2017221196A (ja) | 2011-07-15 | 2017-07-03 | 免疫調節のための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014523252A JP2014523252A (ja) | 2014-09-11 |
| JP2014523252A5 true JP2014523252A5 (enExample) | 2015-09-03 |
| JP6290078B2 JP6290078B2 (ja) | 2018-03-07 |
Family
ID=45563648
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014520633A Active JP6290078B2 (ja) | 2011-07-15 | 2012-07-16 | 免疫調節のための組成物および方法 |
| JP2017130703A Pending JP2017221196A (ja) | 2011-07-15 | 2017-07-03 | 免疫調節のための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017130703A Pending JP2017221196A (ja) | 2011-07-15 | 2017-07-03 | 免疫調節のための組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10106589B2 (enExample) |
| EP (3) | EP2557089A2 (enExample) |
| JP (2) | JP6290078B2 (enExample) |
| AU (1) | AU2012285852B2 (enExample) |
| CA (1) | CA2841994C (enExample) |
| DK (1) | DK2731963T3 (enExample) |
| ES (1) | ES2581278T3 (enExample) |
| PL (1) | PL2731963T3 (enExample) |
| WO (1) | WO2013010998A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2557089A2 (en) * | 2011-07-15 | 2013-02-13 | Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Compositions and methods for immunomodulation |
| SI2968457T1 (sl) | 2013-03-14 | 2018-11-30 | Baxalta Incorporated | Faktor H za transplantacijo |
| CA2929310C (en) | 2013-11-18 | 2024-07-02 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | MICROSPHERE-BASED ADMINISTRATION AND EX VIVO MANIPULATION OF DENDRITE CELLS FOR AUTOIMMUNE THERAPIES |
| FR3018819A1 (fr) * | 2014-03-19 | 2015-09-25 | Univ Bourgogne | Traitement de la reponse inflammatoire et dysimmunitaire |
| EP3384923A1 (en) | 2017-04-06 | 2018-10-10 | Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | C4bp-based compounds for treating immunological diseases |
| EP3808763A1 (en) * | 2019-10-17 | 2021-04-21 | Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Compounds for immunomodulation |
| WO2025172510A1 (en) | 2024-02-15 | 2025-08-21 | Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) | Compounds for treating diseases |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0742235B2 (ja) | 1985-11-08 | 1995-05-10 | 三共株式会社 | 自己免疫性疾病の予防・治療剤 |
| JPH04506460A (ja) * | 1990-01-26 | 1992-11-12 | バイオジェン，インコーポレイテッド | Ｃ４結合タンパク質の融合タンパク質 |
| EP1413587A2 (en) * | 1991-05-03 | 2004-04-28 | Washington University | Modified complement system regulator |
| CA2140343A1 (en) | 1992-07-17 | 1994-02-03 | Sean M. Sullivan | Method and reagent for treatment of animal diseases |
| US6447796B1 (en) | 1994-05-16 | 2002-09-10 | The United States Of America As Represented By The Secretary Of The Army | Sustained release hydrophobic bioactive PLGA microspheres |
| WO1997007128A1 (en) | 1995-08-21 | 1997-02-27 | Duke University | A method to increase the density of antigen on antigen presenting cells |
| US5853719A (en) | 1996-04-30 | 1998-12-29 | Duke University | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
| US6395713B1 (en) | 1997-07-23 | 2002-05-28 | Ribozyme Pharmaceuticals, Inc. | Compositions for the delivery of negatively charged molecules |
| EP2138191A1 (en) | 1998-01-05 | 2009-12-30 | University Of Washington | Enhanced transport using membrane disruptive agents |
| ATE408699T1 (de) | 1999-03-10 | 2008-10-15 | Phogen Ltd | Verabreichung von nukleinsäuren und proteinen an zellen |
| US20020130430A1 (en) | 2000-12-29 | 2002-09-19 | Castor Trevor Percival | Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products |
| WO2002087541A1 (en) | 2001-04-30 | 2002-11-07 | Protiva Biotherapeutics Inc. | Lipid-based formulations for gene transfer |
| US7060498B1 (en) | 2001-11-28 | 2006-06-13 | Genta Salus Llc | Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers |
| US7141540B2 (en) | 2001-11-30 | 2006-11-28 | Genta Salus Llc | Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof |
| JP2005535353A (ja) * | 2002-08-14 | 2005-11-24 | アヴィディス エスアー | Ｃ４ｂｐスカフォールドを使用した、多量体融合タンパク質の産生 |
| US20070104726A1 (en) * | 2002-08-14 | 2007-05-10 | Avidis Sa | Multimeric complexes of antigens and adjuvants |
| WO2005051414A1 (en) | 2003-11-26 | 2005-06-09 | Avidis Sa | Use of c4bp core region as a cd40 agonist |
| WO2005069726A2 (en) * | 2004-01-21 | 2005-08-04 | Case Western Reserve University | Hybrid and chimeric polypeptides that regulate activation of complement |
| EP1790358A1 (en) * | 2005-11-23 | 2007-05-30 | Université de Reims Champagne-Ardennes | Protein constructs designed for targeting and lysis of cells |
| GB0706912D0 (en) * | 2007-04-10 | 2007-05-16 | Isis Innovation | Novel viral vaccines |
| US20090324585A1 (en) * | 2008-06-12 | 2009-12-31 | The Trustees of the Leland Standford Junior University | Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis |
| WO2010091183A2 (en) * | 2009-02-04 | 2010-08-12 | The Regents Of The University Of Colorado, A Body Corporate | Non-invasive detection of complement-mediated inflammation using cr2-targeted nanoparticles |
| EP2557089A2 (en) * | 2011-07-15 | 2013-02-13 | Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Compositions and methods for immunomodulation |
-
2011
- 2011-07-15 EP EP11382240A patent/EP2557089A2/en not_active Withdrawn
-
2012
- 2012-07-16 WO PCT/EP2012/063932 patent/WO2013010998A2/en not_active Ceased
- 2012-07-16 US US14/233,114 patent/US10106589B2/en active Active
- 2012-07-16 DK DK12735156.7T patent/DK2731963T3/en active
- 2012-07-16 EP EP12735156.7A patent/EP2731963B1/en active Active
- 2012-07-16 JP JP2014520633A patent/JP6290078B2/ja active Active
- 2012-07-16 EP EP16156965.2A patent/EP3048111A1/en not_active Withdrawn
- 2012-07-16 PL PL12735156.7T patent/PL2731963T3/pl unknown
- 2012-07-16 CA CA2841994A patent/CA2841994C/en active Active
- 2012-07-16 AU AU2012285852A patent/AU2012285852B2/en active Active
- 2012-07-16 ES ES12735156.7T patent/ES2581278T3/es active Active
-
2017
- 2017-07-03 JP JP2017130703A patent/JP2017221196A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014523252A5 (enExample) | ||
| Xie et al. | Immunoregulatory effects of stem cell-derived extracellular vesicles on immune cells | |
| Strzelec et al. | Immunomodulation—a general review of the current state-of-the-art and new therapeutic strategies for targeting the immune system | |
| D’Alessio et al. | Reparative T lymphocytes in organ injury | |
| Balbi et al. | First characterization of human amniotic fluid stem cell extracellular vesicles as a powerful paracrine tool endowed with regenerative potential | |
| US20190269739A1 (en) | Mesenchymal stem cells populations, their products, and use thereof | |
| EP2861719B1 (en) | Compositions and methods for diminishing an immune response | |
| JP2015529457A5 (enExample) | ||
| Jones et al. | Peripherally induced tolerance depends on peripheral regulatory T cells that require Hopx to inhibit intrinsic IL-2 expression | |
| WO2009134429A2 (en) | Methods and compositions for modulating immunological tolerance | |
| del Rio et al. | CX3CR1+ c-kit+ bone marrow cells give rise to CD103+ and CD103− dendritic cells with distinct functional properties | |
| JP2011523937A5 (enExample) | ||
| JP2017221196A (ja) | 免疫調節のための組成物および方法 | |
| JP2019518003A5 (enExample) | ||
| US20170283769A1 (en) | Modified Cells Evoking Reduced Immunogenic Responses | |
| Bhatt et al. | Biomaterial-assisted local oxygenation safeguards the prostimulatory phenotype and functions of human dendritic cells in hypoxia | |
| Qin et al. | Cardiac cells and mesenchymal stem cells derived extracellular vesicles: a potential therapeutic strategy for myocardial infarction | |
| RU2012146542A (ru) | Способ ингибирования репликации вич в клетках млекопитающих и у людей | |
| Gong et al. | Attenuation of experimental autoimmune myocarditis by si-RNA mediated CD40 silencing | |
| Lee et al. | Microarray analysis after umbilical cord blood derived mesenchymal stem cells injection in monocrotaline-induced pulmonary artery hypertension rats | |
| Coronado | Therapeutic effect of extracellular vesicles derived from adult/perinatal human mesenchymal stem cells | |
| Russell‐Hallinan et al. | Epigenetics of aberrant cardiac wound healing | |
| Wang et al. | CTLA-4 nanovesicles disrupt dendritic cell-driven CD8 T cell priming for myocardial infarction therapy | |
| Jin et al. | Multifaceted mechanisms and targeted delivery of mesenchymal stem cell-derived exosomes in cardiovascular diseases: a translational medicine perspective | |
| EP4060026A1 (en) | Ex-vivo proliferation of human phagocytic cells |